Back to search results

Long-term Weight Loss and Insulin Regulation Study

This study is looking at how much insulin regulation of lipolysis (the breakdown of fats) improves after significant weight loss. Researchers will study people with severe obesity (BMI 40-50 kg/m2) before and about one year after bariatric surgery (gastric sleeve surgery). They want to see if reducing inflammation in fat tissue goes hand-in-hand with better insulin regulation of fat breakdown. You cannot have diabetes, active heart disease, or exercise regularly to participate. The study aims to enroll 30 participants, but its current status is unclear.

Study design
This is an interventional study with an unclear status, planning to enroll 30 participants.
What's involved
You would be assessed before bariatric surgery and again approximately one year after surgery.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for approximately one year after bariatric surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03868592

Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis

Recruiting
NAAges 18–65InterventionalBasic science
Mayo Clinic
~30 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:Gastric sleeve/bariatric surgery

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
adipose macrophage content, adipose IL-6 and TNF gene expression
Measured over Before bariatric surgery and approximately 1 year after surgery
+1 more outcome measured

Conditions

Obesity, Morbid

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Michael D Jensen, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Reich Pamela
[email protected]
5072556062
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

BMI 40 - 50 kg/m2.
Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery

Exclusion

Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
Active coronary artery disease
Participation in structured exercise (\>2 times per week for 30 minutes or longer)
Smoking
Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
Renal insufficiency (serum creatinine \> 1.5mg/dl)
Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
Pregnancy or breastfeeding.

What this trial measures

  • adipose macrophage content, adipose IL-6 and TNF gene expressionBefore bariatric surgery and approximately 1 year after surgery

    Adipose tissue macrophage content as assessed by immunohistochemistry using stains for CD36, CD14 and CD206 will be done. mRNA expression for IL-6 and TNF will be measured

  • insulin regulation of lipolysis (IC50)Before bariatric surgery and approximately 1 year after surgery

    The ability of insulin to suppress FFA palmitate release will be assessed using a 2-step insulin clamp and isotope dilution techniques for palmitate kinetics